Literature DB >> 7947106

Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study.

C A Stiller1, J M Chessells, M Fitchett.   

Abstract

There is a well-known raised risk of leukaemia in children with neurofibromatosis type 1 (NF-1). We carried out the first detailed population-based study of leukaemia and non-Hodgkin lymphoma (NHL) associated with NF-1 in order to estimate the risk and elucidate the relationship between these conditions. Over the 17 year study period there were five cases of chronic myelomonocytic leukaemia (CMML) in patients with NF-1 (relative risk 221; 95% CI 71-514), 12 cases of acute lymphoblastic leukaemia (ALL) (relative risk 5.4; 95% CI 2.8-9.4) and five cases of NHL (relative risk 10.0; 95% CI 3.3-23.4). Marrow cytogenetics could be reviewed for seven patients. Specific abnormalities found were monosomy 21 in a child with CMML and 7p+, 17p- in a child with ALL. No abnormalities were reported of 17q, which includes the NF1 gene. CMML occurred predominantly in boys, who also had a family history of NF-1. ALL and NHL were more often found in children with no previous family history.

Entities:  

Mesh:

Year:  1994        PMID: 7947106      PMCID: PMC2033537          DOI: 10.1038/bjc.1994.431

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  20 in total

1.  GRANULOCYTIC LEUKAEMIA IN CHILDHOOD.

Authors:  R M HARDISTY; D E SPEED; M TILL
Journal:  Br J Haematol       Date:  1964-10       Impact factor: 6.998

2.  Lung-cancer mortality as related to residence and smoking histories. I. White males.

Authors:  W HAENSZEL; D B LOVELAND; M G SIRKEN
Journal:  J Natl Cancer Inst       Date:  1962-04       Impact factor: 13.506

Review 3.  Gliomas in neurofibromatosis: a series of 89 cases with evidence for enhanced malignancy in associated cerebellar astrocytomas.

Authors:  E B Ilgren; L M Kinnier-Wilson; C A Stiller
Journal:  Pathol Annu       Date:  1985

4.  Neurofibromatosis and childhood leukemia.

Authors:  J L Bader; R W Miller
Journal:  J Pediatr       Date:  1978-06       Impact factor: 4.406

5.  Multiple colorectal carcinomas, polyposis coli, and neurofibromatosis.

Authors:  C B Pratt; D M Parham; B H Rao; I D Fleming; R Dilawari
Journal:  J Natl Cancer Inst       Date:  1988-09-21       Impact factor: 13.506

6.  Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis.

Authors:  A G Menon; K M Anderson; V M Riccardi; R Y Chung; J M Whaley; D W Yandell; G E Farmer; R N Freiman; J K Lee; F P Li
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

7.  Proposals for the classification of the myelodysplastic syndromes.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1982-06       Impact factor: 6.998

8.  Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders.

Authors:  K M Shannon; P O'Connell; G A Martin; D Paderanga; K Olson; P Dinndorf; F McCormick
Journal:  N Engl J Med       Date:  1994-03-03       Impact factor: 91.245

9.  Chromosome pattern in juvenile chronic myelogenous leukemia, myelodysplastic syndrome, and acute leukemia associated with neurofibromatosis.

Authors:  Y Kaneko; N Maseki; M Sakurai; A Shibuya; T Shinohara; T Fujimoto; H Kanno; A Nishikawa
Journal:  Leukemia       Date:  1989-01       Impact factor: 11.528

10.  Monosomy 7 in childhood: a myeloproliferative disorder.

Authors:  C A Sieff; J M Chessells; B A Harvey; V J Pickthall; S D Lawler
Journal:  Br J Haematol       Date:  1981-10       Impact factor: 6.998

View more
  61 in total

1.  Four frameshift mutations in neurofibromatosis type 1 caused by small insertions.

Authors:  S D Colman; C R Abernathy; V T Ho; M R Wallace
Journal:  J Med Genet       Date:  1997-07       Impact factor: 6.318

2.  Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin.

Authors:  Trent R Hummel; Walter J Jessen; Shyra J Miller; Lan Kluwe; Victor F Mautner; Margaret R Wallace; Conxi Lázaro; Grier P Page; Paul F Worley; Bruce J Aronow; Elizabeth K Schorry; Nancy Ratner
Journal:  Clin Cancer Res       Date:  2010-08-25       Impact factor: 12.531

Review 3.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

Authors:  Nancy Ratner; Shyra J Miller
Journal:  Nat Rev Cancer       Date:  2015-04-16       Impact factor: 60.716

Review 4.  Therapy-related myeloid neoplasms: pathobiology and clinical characteristics.

Authors:  H Sill; W Olipitz; A Zebisch; E Schulz; A Wölfler
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

Review 5.  [Evaluation of cancer risk through genetic analysis?].

Authors:  A Luz
Journal:  Strahlenther Onkol       Date:  1997-09       Impact factor: 3.621

6.  The GAP-related domain of neurofibromin attenuates proliferation and downregulates N- and K-Ras activation in Nf1-negative AML cells.

Authors:  Kelly J Morgan; Matthew A Rowley; Stephen M Wiesner; Diane E Hasz; Brian Van Ness; David A Largaespada
Journal:  Leuk Res       Date:  2007-01-12       Impact factor: 3.156

7.  Increased frequency of hematopoietic malignancies in relatives of patients with lymphoid neoplasms: a French case-control study.

Authors:  Sara Villeneuve; Laurent Orsi; Alain Monnereau; Christian Berthou; Pierre Fenaux; Gerald Marit; Pierre Soubeyran; Françoise Huguet; Noël Milpied; Michel Leporrier; Denis Hemon; Xavier Troussard; Jacqueline Clavel
Journal:  Int J Cancer       Date:  2009-03-01       Impact factor: 7.396

Review 8.  Pediatric low-grade gliomas.

Authors:  Angela J Sievert; Michael J Fisher
Journal:  J Child Neurol       Date:  2009-11       Impact factor: 1.987

9.  fdg-pet in two cases of neurofibromatosis type 1 and atypical malignancies.

Authors:  P de Blank; K Cole; L Kersun; A Green; J J Wilkes; J Belasco; R Bagatell; L C Bailey; M J Fisher
Journal:  Curr Oncol       Date:  2014-04       Impact factor: 3.677

10.  Expression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomas.

Authors:  Matthew J Frank; David W Dawson; Steven J Bensinger; Jason S Hong; Wendy M Knosp; Lizhong Xu; Cynthia E Balatoni; Eric L Allen; Rhine R Shen; Dafna Bar-Sagi; Gail R Martin; Michael A Teitell
Journal:  Blood       Date:  2009-01-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.